In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Loxo Oncology Inc. (NASDAQ:LOXO) reported that Access Industries Management, Llc. has picked up 2,080,897 of common stock as of 2017-01-18.
The acquisition brings the aggregate amount owned by Access Industries Management, Llc. to a total of 2,080,897 representing a 8.15% stake in the company.
For those not familiar with the company, Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity.
A glance at Loxo Oncology Inc. (NASDAQ:LOXO)’s key stats reveals a current market capitalization of 947.01 million based on 25.55 million shares outstanding and a price at last close of $37.61 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-10, Aisling picked up 160,000 at a purchase price of $31.00. This brings their total holding to 4,188,920 as of the date of the filing.
On the sell side, the most recent transaction saw Flaherty unload 7,250 shares at a sale price of $30.23. This brings their total holding to 38,732.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Loxo Oncology Inc. (NASDAQ:LOXO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
